Conmed (CNMD) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
CONMED (CNMD) PT Raised to $73 at Needham & Company
April 26, 2018 6:54 AM EDTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $73.00 (from $71.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 1Q18 revenue and EPS beat consensus and management raised its 2018 revenue and EPS guidance. Revenue growth slowed somewhat to 6.8% CC... More
